Research progress of type Ⅰ collagen in osteoporosis_West China Medical Journal

Authors：

WU Yuangang , ZENG Yi ,  SHEN Bin

Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

SHEN Bin, Email: shenbin_1971@163.com

Keywords：

Osteoporosis; Type Ⅰ collagen fibers; Biomechanics

DOI：

10.7507/1002-0179.201907169

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Osteoporosis is a degenerative disease characterized by decreased bone mass and destruction of bone microstructure. At present, previous studies have found that the structure and content of type Ⅰ collagen fibers are closely related to osteoporosis. However, there have been few studies on the prevention and treatment of osteoporosis using type Ⅰ collagen fibers as therapeutic targets. In this paper, the relationships between type Ⅰ collagen fibers and osteoporosis, biomechanics, bone matrix and bone strength are discussed. At the same time, the regulation of type Ⅰ collagen-related signaling pathways in osteoporosis is summarized, such as the signaling pathways of cathepsin K, transforming growth factor-β/Sma- and Mad-related protein, transforming growth factor-β/bone morphogenetic protein, c-jun N-terminal protein kinase and Wnt/β-catenin, in order to provide a new therapeutic direction for the prevention and treatment of osteoporosis.

Citation： WU Yuangang, ZENG Yi, SHEN Bin. Research progress of type Ⅰ collagen in osteoporosis. West China Medical Journal, 2019, 34(9): 1047-1052. doi: 10.7507/1002-0179.201907169 Copy

1.	Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol, 2017, 4(1): 46-56.
2.	Nakatoh S. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol. J Bone Miner Metab, 2018, 36(2): 221-228.
3.	Eftekhar-Sadat B, Ghavami M, Toopchizadeh V, et al. Wrist bone mineral density utility in diagnosing hip osteoporosis in postmenopausal women. Ther Adv Endocrinol Metab, 2016, 7(5/6): 207-211.
4.	Kalluru R, Petrie KJ, Grey A, et al. Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open, 2017, 7(2): e013703.
5.	Zhang Y, Liu M, Li H, et al. Traditional Chinese medicine Bushen-Jianpi-Huoxue decoction prevents diabetic osteoporosis in rats via Wnt and nuclear factor-kappa B signaling pathways. Int J Rheum Dis, 2017, 20(8): 941-948.
6.	Li S, Sun T, Liu Z. Excess mortality of 1 year in elderly hip fracture patients compared with the general population in Beijing, China. Arch Osteoporos, 2016, 11(1): 35.
7.	Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res, 2014, 29(11): 2520-2526.
8.	Elffors I, Allander E, Kanis JA, et al. The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int, 1994, 4(5): 253-263.
9.	Bradley CA. Osteoporosis: community-based screening reduces hip fracture risk. Nat Rev Endocrinol, 2018, 14(3): 129.
10.	Rapp K, Rothenbacher D, Magaziner J, et al. Risk of nursing home admission after femoral fracture compared with stroke, myocardial infarction, and pneumonia. J Am Med Dir Assoc, 2015, 16(8): 715.e7-715.e12.
11.	Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med, 2017, 167(3): ITC17-ITC32.
12.	Wu J, Yu M, Zhou Y. Association of collagen type I alpha 1 +1245G/T polymorphism and osteoporosis risk in post-menopausal women: a meta-analysis. Int J Rheum Dis, 2017, 20(7): 903-910.
13.	Sakai A, Ito M, Tomomitsu T, et al. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis. Osteoporos Int, 2015, 26(3): 1193-1202.
14.	Hong HS, Um J, Lee ZH, et al. Long-term comparative study of substance-P with methylprednisolone on the development of osteoporosis. J Toxicol Sci, 2014, 39(3): 391-399.
15.	Nagaoka H, Terajima M, Yamada S, et al. Alfacalcidol enhances collagen quality in ovariectomized rat bones. J Orthop Res, 2014, 32(8): 1030-1036.
16.	Chubb SA, Mandelt C, Vasikaran S. Comparison of clinical cut-points and treatment targets for urine NTX and plasma βCTX-I in osteoporosis. Clin Biochem, 2016, 49(7-8): 529-533.
17.	Karunaratne A, Xi L, Bentley L, et al. Multiscale alterations in bone matrix quality increased fragility in steroid induced osteoporosis. Bone, 2016, 84: 15-24.
18.	Deng WM, Wei QS, Tan X, et al. Relation of serum 25 hydroxyvitamin D levels to bone mineral density in southern Chinese postmenopausal women: a preliminary study. Indian J Med Res, 2015, 142(4): 430-437.
19.	Gopinathan NR, Sen RK, Behera P, et al. Awareness of osteoporosis in postmenopausal Indian women: an evaluation of Osteoporosis Health Belief Scale. J Midlife Health, 2016, 7(4): 180-184.
20.	Diez-Perez A, Naylor KE, Abrahamsen B, et al. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int, 2017, 28(3): 767-774.
21.	Diehl N, Johnson MM. Prevalence of osteopenia and osteoporosis in patients with noncystic fibrosis bronchiectasis. South Med J, 2016, 109(12): 779-783.
22.	Li JJ, Wang BQ, Fei Q, et al. Identification of candidate genes in osteoporosis by integrated microarray analysis. Bone Joint Res, 2016, 5(12): 594-601.
23.	Newell N, Little JP, Christou A, et al. Biomechanics of the human intervertebral disc: a review of testing techniques and results. J Mech Behav Biomed Mater, 2017, 69: 420-434.
24.	Livermore A, Tueting JL. Biomechanics of tendon transfers. Hand Clin, 2016, 32(3): 291-302.
25.	Tyagi SK, Aithal HP, Kinjavdekar P, et al. In vitro biomechanical testing of different configurations of acrylic external skeletal fixator constructs. Vet Comp Orthop Traumatol, 2015, 28(4): 227-233.
26.	Saltzman BM, Erickson BJ, Frank JM, et al. Biomechanical testing of the reconstructed ulnar collateral ligament: a systematic review of the literature. Musculoskelet Surg, 2016, 100(3): 157-163.
27.	Gebauer M, Stark O, Vettorazzi E, et al. DXA and pQCT predict pertrochanteric and not femoral neck fracture load in a human side-impact fracture model. J Orthop Res, 2014, 32(1): 31-38.
28.	Kadler KE, Baldock C, Bella J, et al. Collagens at a glance. J Cell Sci, 2007, 120(12): 1955-1958.
29.	Zafiropoulos GG, Deli G, Hoffmann O, et al. Changes of the peri-implant soft tissue thickness after grafting with a collagen matrix. J Indian Soc Periodontol, 2016, 20(4): 441-445.
30.	Nair AK, Gautieri A, Chang SW, et al. Molecular mechanics of mineralized collagen fibrils in bone. Nat Commun, 2013, 4: 1724.
31.	Svensson RB, Hansen P, Hassenkam T, et al. Mechanical properties of human patellar tendon at the hierarchical levels of tendon and fibril. J Appl Physiol (1985), 2012, 112(3): 419-426.
32.	Haynl C, Hofmann E, Pawar K, et al. Microfluidics-produced collagen fibers show extraordinary mechanical properties. Nano Lett, 2016, 16(9): 5917-5922.
33.	Viguet-Carrin S, Garnero P, Delmas PD. The role of collagen in bone strength. Osteoporos Int, 2006, 17(3): 319-336.
34.	Marini JC, Forlino A, Bächinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers, 2017, 3: 17052.
35.	Palomo T, Vilaça T, Lazaretti-Castro M. Osteogenesis imperfecta: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes, 2017, 24(6): 381-388.
36.	Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat, 2007, 28(3): 209-221.
37.	Marotti G, Muglia MA, Palumbo C. Structure and function of lamellar bone. Clin Rheumatol, 1994, 13(Suppl 1): 63-68.
38.	Depalle B, Qin Z, Shefelbine SJ, et al. Influence of cross-link structure, density and mechanical properties in the mesoscale deformation mechanisms of collagen fibrils. J Mech Behav Biomed Mater, 2015, 52: 1-13.
39.	Fazaeli S, Ghazanfari S, Everts V, et al. The contribution of collagen fibers to the mechanical compressive properties of the temporomandibular joint disc. Osteoarthritis Cartilage, 2016, 24(7): 1292-1301.
40.	Bertassoni LE, Swain MV. Removal of dentin non-collagenous structures results in the unraveling of microfibril bundles in collagen type I. Connect Tissue Res, 2017, 58(5): 414-423.
41.	Franzone JM, Shah SA, Wallace MJ, et al. Osteogenesis imperfecta: a pediatric orthopedic perspective. Orthop Clin North Am, 2019, 50(2): 193-209.
42.	Fantner GE, Birkedal H, Kindt JH, et al. Influence of the degradation of the organic matrix on the microscopic fracture behavior of trabecular bone. Bone, 2004, 35(5): 1013-1022.
43.	Qiu ZC, Dong XL, Dai Y, et al. Discovery of a new class of cathepsin K inhibitors in rhizoma drynariae as potential candidates for the treatment of osteoporosis. Int J Mol Sci, 2016, 17(12): pii: E2116.
44.	Novinec M, Rebernik M, Lenarčič B. An allosteric site enables fine-tuning of cathepsin K by diverse effectors. FEBS Lett, 2016, 590(24): 4507-4518.
45.	Brömme D, Panwar P, Turan S. Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: commonalities and differences. Expert Opin Drug Discov, 2016, 11(5): 457-472.
46.	Barbarash OL, Lebedeva NB, Kokov AN, et al. Decreased cathepsin K plasma level may reflect an association of osteopoenia/osteoporosis with coronary atherosclerosis and coronary artery calcification in male patients with stable angina. Heart Lung Circ, 2016, 25(7): 691-697.
47.	Panwar P, Du X, Sharma V, et al. Effects of cysteine proteases on the structural and mechanical properties of collagen fibers. J Biol Chem, 2013, 288(8): 5940-5950.
48.	Chapurlat RD. Treatment of postmenopausal osteoporosis with odanacatib. Expert Opin Pharmacother, 2014, 15(4): 559-564.
49.	Serita S, Tomokiyo A, Hasegawa D, et al. Transforming growth factor-β-induced gene product-h3 inhibits odontoblastic differentiation of dental pulp cells. Arch Oral Biol, 2017, 78: 135-143.
50.	Prabhu MA, Ismael S, Remani K, et al. Association of transforming growth factor-β superfamily genes with non-regression of pulmonary artery hypertension following balloon mitral valvotomy: a pilot study. J Heart Valve Dis, 2016, 25(6): 708-715.
51.	MacFarlane EG, Haupt J, Dietz HC, et al. TGF-β family signaling in connective tissue and skeletal diseases. Cold Spring Harb Perspect Biol, 2017, 9(11).
52.	Komatsu Y, Ibi M, Chosa N, et al. Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts. Int J Mol Med, 2016, 38(1): 139-147.
53.	Smaldone S, Clayton NP, del Solar M, et al. Fibrillin-1 regulates skeletal stem cell differentiation by modulating TGFβ activity within the marrow niche. J Bone Miner Res, 2016, 31(1): 86-97.
54.	Pincu Y, Linden MA, Zou K, et al. The effects of high fat diet and moderate exercise on TGFβ1 and collagen deposition in mouse skeletal muscle. Cytokine, 2015, 73(1): 23-29.
55.	Berria R, Wang L, Richardson DK, et al. Increased collagen content in insulin-resistant skeletal muscle. Am J Physiol Endocrinol Metab, 2006, 290(3): E560-E565.
56.	Zhang Q, Oh JH, Park CH, et al. Effects of Dimethyloxalylglycine-embedded poly(ε-caprolactone) fiber meshes on wound healing in diabetic rats. ACS Appl Mater Interfaces, 2017, 9(9): 7950-7963.
57.	Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet, 2004, 363(9418): 1377-1385.
58.	Symoens S, Steyaert W, Demuynck L, et al. Tissue-specific mosaicism for a lethal osteogenesis imperfecta COL1A1 mutation causes mild OI/EDS overlap syndrome. Am J Med Genet A, 2017, 173(4): 1047-1050.
59.	Oestreich AK, Kamp WM, McCray MG, et al. Decreasing maternal myostatin programs adult offspring bone strength in a mouse model of osteogenesis imperfecta. Proc Natl Acad Sci USA, 2016, 113(47): 13522-13527.
60.	Dwan K, Phillipi CA, Steiner RD, et al. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev, 2016, 10: CD005088.
61.	Bi X, Grafe I, Ding H, et al. Correlations between bone mechanical properties and bone composition parameters in mouse models of dominant and recessive osteogenesis imperfecta and the response to anti-TGF-β treatment. J Bone Miner Res, 2017, 32(2): 347-359.
62.	Ahn SJ, Baek JM, Cheon YH, et al. The Inhibitory effect of angelica tenuissima water extract on receptor activator of nuclear factor-kappa-b ligand-induced osteoclast differentiation and bone resorbing activity of mature osteoclasts. Am J Chin Med, 2015, 43(4): 715-729.
63.	Yang DH, Moon SW, Lee DW. Surface modification of titanium with BMP-2/GDF-5 by a heparin linker and its efficacy as a dental implant. Int J Mol Sci, 2017, 18(1): pii: E229.
64.	Shi C, Zhang H, Louie K, et al. BMP signaling mediated by BMPR1A in osteoclasts negatively regulates osteoblast mineralization through suppression of Cx43. J Cell Biochem, 2017, 118(3): 605-614.
65.	Fujioka-Kobayashi M, Schaller B, Saulacic N, et al. Growth factor delivery of BMP9 using a novel natural bovine bone graft with integrated atelo-collagen type I: biosynthesis, characterization, and cell behavior. J Biomed Mater Res A, 2017, 105(2): 408-418.
66.	Fu A, Wang Y, Wu Y, et al. Echinacea purpurea extract polarizes M1 macrophages in murine bone marrow-derived macrophages through the activation of JNK. J Cell Biochem, 2017, 118(9): 2664-2671.
67.	Guo CH, Bai L, Wu HH, et al. The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain. Int J Mol Med, 2016, 38(5): 1433-1442.
68.	Guo Y, Li L, Gao J, et al. miR-214 suppresses the osteogenic differentiation of bone marrow-derived mesenchymal stem cells and these effects are mediated through the inhibition of the JNK and p38 pathways. Int J Mol Med, 2017, 39(1): 71-80.
69.	Jing D, Zhai M, Tong S, et al. Pulsed electromagnetic fields promote osteogenesis and osseointegration of porous titanium implants in bone defect repair through a Wnt/β-catenin signaling-associated mechanism. Sci Rep, 2016, 6: 32045.
70.	Ikehata M, Yamada A, Morimura N, et al. Wnt/β-catenin signaling activates nephronectin expression in osteoblasts. Biochem Biophys Res Commun, 2017, 484(2): 231-234.
71.	Chang MK, Kramer I, Keller H, et al. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res, 2014, 29(1): 29-42.
72.	Wang Y, Li YP, Paulson C, et al. Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed), 2014, 19: 379-407.
73.	Sun X, Wang H, Huang W, et al. Inhibition of bone formation in rats by aluminum exposure via Wnt/β-catenin pathway. Chemosphere, 2017, 176: 1-7.
74.	Ying X, Chen X, Feng Y, et al. Myricetin enhances osteogenic differentiation through the activation of canonical Wnt/β-catenin signaling in human bone marrow stromal cells. Eur J Pharmacol, 2014, 738: 22-30.

1. Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol, 2017, 4(1): 46-56.
2. Nakatoh S. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol. J Bone Miner Metab, 2018, 36(2): 221-228.
3. Eftekhar-Sadat B, Ghavami M, Toopchizadeh V, et al. Wrist bone mineral density utility in diagnosing hip osteoporosis in postmenopausal women. Ther Adv Endocrinol Metab, 2016, 7(5/6): 207-211.
4. Kalluru R, Petrie KJ, Grey A, et al. Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open, 2017, 7(2): e013703.
5. Zhang Y, Liu M, Li H, et al. Traditional Chinese medicine Bushen-Jianpi-Huoxue decoction prevents diabetic osteoporosis in rats via Wnt and nuclear factor-kappa B signaling pathways. Int J Rheum Dis, 2017, 20(8): 941-948.
6. Li S, Sun T, Liu Z. Excess mortality of 1 year in elderly hip fracture patients compared with the general population in Beijing, China. Arch Osteoporos, 2016, 11(1): 35.
7. Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res, 2014, 29(11): 2520-2526.
8. Elffors I, Allander E, Kanis JA, et al. The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int, 1994, 4(5): 253-263.
9. Bradley CA. Osteoporosis: community-based screening reduces hip fracture risk. Nat Rev Endocrinol, 2018, 14(3): 129.
10. Rapp K, Rothenbacher D, Magaziner J, et al. Risk of nursing home admission after femoral fracture compared with stroke, myocardial infarction, and pneumonia. J Am Med Dir Assoc, 2015, 16(8): 715.e7-715.e12.
11. Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med, 2017, 167(3): ITC17-ITC32.
12. Wu J, Yu M, Zhou Y. Association of collagen type I alpha 1 +1245G/T polymorphism and osteoporosis risk in post-menopausal women: a meta-analysis. Int J Rheum Dis, 2017, 20(7): 903-910.
13. Sakai A, Ito M, Tomomitsu T, et al. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis. Osteoporos Int, 2015, 26(3): 1193-1202.
14. Hong HS, Um J, Lee ZH, et al. Long-term comparative study of substance-P with methylprednisolone on the development of osteoporosis. J Toxicol Sci, 2014, 39(3): 391-399.
15. Nagaoka H, Terajima M, Yamada S, et al. Alfacalcidol enhances collagen quality in ovariectomized rat bones. J Orthop Res, 2014, 32(8): 1030-1036.
16. Chubb SA, Mandelt C, Vasikaran S. Comparison of clinical cut-points and treatment targets for urine NTX and plasma βCTX-I in osteoporosis. Clin Biochem, 2016, 49(7-8): 529-533.
17. Karunaratne A, Xi L, Bentley L, et al. Multiscale alterations in bone matrix quality increased fragility in steroid induced osteoporosis. Bone, 2016, 84: 15-24.
18. Deng WM, Wei QS, Tan X, et al. Relation of serum 25 hydroxyvitamin D levels to bone mineral density in southern Chinese postmenopausal women: a preliminary study. Indian J Med Res, 2015, 142(4): 430-437.
19. Gopinathan NR, Sen RK, Behera P, et al. Awareness of osteoporosis in postmenopausal Indian women: an evaluation of Osteoporosis Health Belief Scale. J Midlife Health, 2016, 7(4): 180-184.
20. Diez-Perez A, Naylor KE, Abrahamsen B, et al. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int, 2017, 28(3): 767-774.
21. Diehl N, Johnson MM. Prevalence of osteopenia and osteoporosis in patients with noncystic fibrosis bronchiectasis. South Med J, 2016, 109(12): 779-783.
22. Li JJ, Wang BQ, Fei Q, et al. Identification of candidate genes in osteoporosis by integrated microarray analysis. Bone Joint Res, 2016, 5(12): 594-601.
23. Newell N, Little JP, Christou A, et al. Biomechanics of the human intervertebral disc: a review of testing techniques and results. J Mech Behav Biomed Mater, 2017, 69: 420-434.
24. Livermore A, Tueting JL. Biomechanics of tendon transfers. Hand Clin, 2016, 32(3): 291-302.
25. Tyagi SK, Aithal HP, Kinjavdekar P, et al. In vitro biomechanical testing of different configurations of acrylic external skeletal fixator constructs. Vet Comp Orthop Traumatol, 2015, 28(4): 227-233.
26. Saltzman BM, Erickson BJ, Frank JM, et al. Biomechanical testing of the reconstructed ulnar collateral ligament: a systematic review of the literature. Musculoskelet Surg, 2016, 100(3): 157-163.
27. Gebauer M, Stark O, Vettorazzi E, et al. DXA and pQCT predict pertrochanteric and not femoral neck fracture load in a human side-impact fracture model. J Orthop Res, 2014, 32(1): 31-38.
28. Kadler KE, Baldock C, Bella J, et al. Collagens at a glance. J Cell Sci, 2007, 120(12): 1955-1958.
29. Zafiropoulos GG, Deli G, Hoffmann O, et al. Changes of the peri-implant soft tissue thickness after grafting with a collagen matrix. J Indian Soc Periodontol, 2016, 20(4): 441-445.
30. Nair AK, Gautieri A, Chang SW, et al. Molecular mechanics of mineralized collagen fibrils in bone. Nat Commun, 2013, 4: 1724.
31. Svensson RB, Hansen P, Hassenkam T, et al. Mechanical properties of human patellar tendon at the hierarchical levels of tendon and fibril. J Appl Physiol (1985), 2012, 112(3): 419-426.
32. Haynl C, Hofmann E, Pawar K, et al. Microfluidics-produced collagen fibers show extraordinary mechanical properties. Nano Lett, 2016, 16(9): 5917-5922.
33. Viguet-Carrin S, Garnero P, Delmas PD. The role of collagen in bone strength. Osteoporos Int, 2006, 17(3): 319-336.
34. Marini JC, Forlino A, Bächinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers, 2017, 3: 17052.
35. Palomo T, Vilaça T, Lazaretti-Castro M. Osteogenesis imperfecta: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes, 2017, 24(6): 381-388.
36. Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat, 2007, 28(3): 209-221.
37. Marotti G, Muglia MA, Palumbo C. Structure and function of lamellar bone. Clin Rheumatol, 1994, 13(Suppl 1): 63-68.
38. Depalle B, Qin Z, Shefelbine SJ, et al. Influence of cross-link structure, density and mechanical properties in the mesoscale deformation mechanisms of collagen fibrils. J Mech Behav Biomed Mater, 2015, 52: 1-13.
39. Fazaeli S, Ghazanfari S, Everts V, et al. The contribution of collagen fibers to the mechanical compressive properties of the temporomandibular joint disc. Osteoarthritis Cartilage, 2016, 24(7): 1292-1301.
40. Bertassoni LE, Swain MV. Removal of dentin non-collagenous structures results in the unraveling of microfibril bundles in collagen type I. Connect Tissue Res, 2017, 58(5): 414-423.
41. Franzone JM, Shah SA, Wallace MJ, et al. Osteogenesis imperfecta: a pediatric orthopedic perspective. Orthop Clin North Am, 2019, 50(2): 193-209.
42. Fantner GE, Birkedal H, Kindt JH, et al. Influence of the degradation of the organic matrix on the microscopic fracture behavior of trabecular bone. Bone, 2004, 35(5): 1013-1022.
43. Qiu ZC, Dong XL, Dai Y, et al. Discovery of a new class of cathepsin K inhibitors in rhizoma drynariae as potential candidates for the treatment of osteoporosis. Int J Mol Sci, 2016, 17(12): pii: E2116.
44. Novinec M, Rebernik M, Lenarčič B. An allosteric site enables fine-tuning of cathepsin K by diverse effectors. FEBS Lett, 2016, 590(24): 4507-4518.
45. Brömme D, Panwar P, Turan S. Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: commonalities and differences. Expert Opin Drug Discov, 2016, 11(5): 457-472.
46. Barbarash OL, Lebedeva NB, Kokov AN, et al. Decreased cathepsin K plasma level may reflect an association of osteopoenia/osteoporosis with coronary atherosclerosis and coronary artery calcification in male patients with stable angina. Heart Lung Circ, 2016, 25(7): 691-697.
47. Panwar P, Du X, Sharma V, et al. Effects of cysteine proteases on the structural and mechanical properties of collagen fibers. J Biol Chem, 2013, 288(8): 5940-5950.
48. Chapurlat RD. Treatment of postmenopausal osteoporosis with odanacatib. Expert Opin Pharmacother, 2014, 15(4): 559-564.
49. Serita S, Tomokiyo A, Hasegawa D, et al. Transforming growth factor-β-induced gene product-h3 inhibits odontoblastic differentiation of dental pulp cells. Arch Oral Biol, 2017, 78: 135-143.
50. Prabhu MA, Ismael S, Remani K, et al. Association of transforming growth factor-β superfamily genes with non-regression of pulmonary artery hypertension following balloon mitral valvotomy: a pilot study. J Heart Valve Dis, 2016, 25(6): 708-715.
51. MacFarlane EG, Haupt J, Dietz HC, et al. TGF-β family signaling in connective tissue and skeletal diseases. Cold Spring Harb Perspect Biol, 2017, 9(11).
52. Komatsu Y, Ibi M, Chosa N, et al. Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts. Int J Mol Med, 2016, 38(1): 139-147.
53. Smaldone S, Clayton NP, del Solar M, et al. Fibrillin-1 regulates skeletal stem cell differentiation by modulating TGFβ activity within the marrow niche. J Bone Miner Res, 2016, 31(1): 86-97.
54. Pincu Y, Linden MA, Zou K, et al. The effects of high fat diet and moderate exercise on TGFβ1 and collagen deposition in mouse skeletal muscle. Cytokine, 2015, 73(1): 23-29.
55. Berria R, Wang L, Richardson DK, et al. Increased collagen content in insulin-resistant skeletal muscle. Am J Physiol Endocrinol Metab, 2006, 290(3): E560-E565.
56. Zhang Q, Oh JH, Park CH, et al. Effects of Dimethyloxalylglycine-embedded poly(ε-caprolactone) fiber meshes on wound healing in diabetic rats. ACS Appl Mater Interfaces, 2017, 9(9): 7950-7963.
57. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet, 2004, 363(9418): 1377-1385.
58. Symoens S, Steyaert W, Demuynck L, et al. Tissue-specific mosaicism for a lethal osteogenesis imperfecta COL1A1 mutation causes mild OI/EDS overlap syndrome. Am J Med Genet A, 2017, 173(4): 1047-1050.
59. Oestreich AK, Kamp WM, McCray MG, et al. Decreasing maternal myostatin programs adult offspring bone strength in a mouse model of osteogenesis imperfecta. Proc Natl Acad Sci USA, 2016, 113(47): 13522-13527.
60. Dwan K, Phillipi CA, Steiner RD, et al. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev, 2016, 10: CD005088.
61. Bi X, Grafe I, Ding H, et al. Correlations between bone mechanical properties and bone composition parameters in mouse models of dominant and recessive osteogenesis imperfecta and the response to anti-TGF-β treatment. J Bone Miner Res, 2017, 32(2): 347-359.
62. Ahn SJ, Baek JM, Cheon YH, et al. The Inhibitory effect of angelica tenuissima water extract on receptor activator of nuclear factor-kappa-b ligand-induced osteoclast differentiation and bone resorbing activity of mature osteoclasts. Am J Chin Med, 2015, 43(4): 715-729.
63. Yang DH, Moon SW, Lee DW. Surface modification of titanium with BMP-2/GDF-5 by a heparin linker and its efficacy as a dental implant. Int J Mol Sci, 2017, 18(1): pii: E229.
64. Shi C, Zhang H, Louie K, et al. BMP signaling mediated by BMPR1A in osteoclasts negatively regulates osteoblast mineralization through suppression of Cx43. J Cell Biochem, 2017, 118(3): 605-614.
65. Fujioka-Kobayashi M, Schaller B, Saulacic N, et al. Growth factor delivery of BMP9 using a novel natural bovine bone graft with integrated atelo-collagen type I: biosynthesis, characterization, and cell behavior. J Biomed Mater Res A, 2017, 105(2): 408-418.
66. Fu A, Wang Y, Wu Y, et al. Echinacea purpurea extract polarizes M1 macrophages in murine bone marrow-derived macrophages through the activation of JNK. J Cell Biochem, 2017, 118(9): 2664-2671.
67. Guo CH, Bai L, Wu HH, et al. The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain. Int J Mol Med, 2016, 38(5): 1433-1442.
68. Guo Y, Li L, Gao J, et al. miR-214 suppresses the osteogenic differentiation of bone marrow-derived mesenchymal stem cells and these effects are mediated through the inhibition of the JNK and p38 pathways. Int J Mol Med, 2017, 39(1): 71-80.
69. Jing D, Zhai M, Tong S, et al. Pulsed electromagnetic fields promote osteogenesis and osseointegration of porous titanium implants in bone defect repair through a Wnt/β-catenin signaling-associated mechanism. Sci Rep, 2016, 6: 32045.
70. Ikehata M, Yamada A, Morimura N, et al. Wnt/β-catenin signaling activates nephronectin expression in osteoblasts. Biochem Biophys Res Commun, 2017, 484(2): 231-234.
71. Chang MK, Kramer I, Keller H, et al. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res, 2014, 29(1): 29-42.
72. Wang Y, Li YP, Paulson C, et al. Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed), 2014, 19: 379-407.
73. Sun X, Wang H, Huang W, et al. Inhibition of bone formation in rats by aluminum exposure via Wnt/β-catenin pathway. Chemosphere, 2017, 176: 1-7.
74. Ying X, Chen X, Feng Y, et al. Myricetin enhances osteogenic differentiation through the activation of canonical Wnt/β-catenin signaling in human bone marrow stromal cells. Eur J Pharmacol, 2014, 738: 22-30.

West China Medical Journal

Research progress of type Ⅰ collagen in osteoporosis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content